Heartflow, Inc. 8K

Heartflow, Inc. reported strong Q2 2026 results and raised its full-year 2026 revenue and non-GAAP gross margin guidance, reflecting accelerating growth in its AI-driven coronary artery disease diagnostics platform despite continued net losses.

Heartflow, Inc. filed a Form 8-K to furnish its second quarter 2026 financial results and updated full-year 2026 guidance, reporting $64.1 million in revenue (up 48% year-over-year), 83.0% GAAP gross margin, a GAAP net loss of $15.7 million (non-GAAP net loss of $5.8 million) and adjusted EBITDA of -$6.7 million, alongside strong U.S. case volume growth in its FFRCT and Plaque businesses. The company highlighted improved gross margin driven by scale and AI-driven productivity initiatives, higher operating expenses from increased sales, technology, and clinical research investments, and cash, cash equivalents and investments totaling $246.8 million as of June 30, 2026. Management raised full-year 2026 guidance to revenue of $246–$250 million (approximately 40%–42% growth year-over-year) and non-GAAP gross margin of about 82%, reflecting growing confidence in the scalability of its AI-powered CAD diagnostic platform. The 8-K also announced details of a same-day webcast and conference call to discuss the results and included extensive non-GAAP reconciliations and forward-looking statements regarding market opportunities, profitability, and associated risks.

Filing Facts

CIK

1464521

Ticker

-

Form

8K

Source Type

sec

Accession

0001464521-26-000129

Alert Tier

7